| 摘要: |
| 目的:研究他克莫司联合激素治疗儿童激素抵抗性肾病综合征的临床效果。方法:选取在我院治疗的30例激素抵抗性肾病综合征患儿随机分为试验组和对照组各15例,试验组采用他克莫司加激素治疗,对照组采用环磷酰胺加激素治疗,观察两组患儿治疗3个月及6个月后24 h尿蛋白定量、血浆白蛋白水平、临床疗效以及不良反应发生情况。结果:与对照组比较,试验组患儿治疗6个月后24 h尿蛋白定量水平降低,血浆白蛋白水平升高(P均<0.05);试验组患儿临床症状缓解有效率高于对照
组,差异有统计学意义(P<0.05);试验组患儿消化道症状、肝毒性、高血压等不良反应发生率为20.0%,低于对照组的66.7%,
差异有统计学意义(P<0.05)。结论:他克莫司联合激素治疗儿童激素抵抗性肾病综合征较环磷酰胺联合激素治疗的临床疗效
好且不良反应更少,值得临床推广应用。 |
| 关键词: 他克莫司 激素 儿童 肾病综合征 |
| DOI：doi:10.13407/j.cnki.jpp.1672-108X.2018.11.005 |
|
| 基金项目: |
|
| Tacrolimus Combined with Hormone Therapy in the Treatment of Children with Hormone-Resistant Nephrotic Syndrome |
| Zhou Jun, Wang Zhenzhen, Wu Limin, Zhang Haiyan |
| (Xiaogan Central Hospital of Hubei, Hubei Xiaogan 432000, China) |
| Abstract: |
| Objective: To investigate the clinical treatment of tacrolimus combined with hormone therapy in the treatment of children with hormone-resistant nephrotic syndrome. Methods: Totally 30 children with hormone-resistant nephrotic syndrome admitted into our
hospital were extracted to be randomly divided into treatment group and control group, with 15 cases in each group. The treatment group received tacrolimus combined with hormone, while the control group was given cyclophosphamide combined with hormone. 24 h urinary protein quantification, plasma albumin level, clinical efficacy and adverse drug reactions of two groups were observed at 3 and 6 months after treatment. Results: Compared with the control group, the level of 24 h urinary protein quantification of treatment group decreased significantly, while plasma albumin level increased significantly (P<0.05). The response rate of clinical symptoms was significantly higher in the treatment group than in the control group (P<0.05). The incidence of adverse drug reactions including gastrointestinal symptoms, hepatotoxicity and hypertension in the treatment group was 20.0%, lower than 66.7% of the control group, the difference was statistically significant (P<0.05). Conclusion: Tacrolimus combined with hormone therapy in the treatment of children with hormone-resistant nephrotic syndrome has better clinical efficacy and less adverse drug reactions than cyclophosphamide, and it is worthy of clinical application. |
| Key words: tacrolimus hormone children nephritic syndrome |
